Yeast-Based Phenotypic Screening for Viral RNA Capping Enzymes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack robust platforms for high-throughput screening of inhibitors targeting viral RNA capping enzymes, which are essential for viral replication and immune evasion, particularly for emerging pathogens like SARS-CoV-2, MERS-CoV, and African Swine Fever virus.
Innovation Solution
Development of yeast-based phenotypic platforms, such as YeRCOM, for functional characterization and targeting of RNA capping enzymes, enabling high-throughput screening and identification of inhibitors, and directed evolution to identify attenuation mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional in vitro enzyme assays and pathogenic replicons are used to screen for inhibitors of RNA capping enzymes, then functional characterization can be achieved, but high-throughput screening capability is limited
Solution Approach 1:
The patent uses yeast cells as an intermediary platform to screen for inhibitors of viral RNA capping enzymes. The yeast expression system serves as a mediator between the complex viral enzyme assays and high-throughput screening capabilities, enabling automated compound testing while maintaining functional relevance to viral replication.
Solution Approach 2:
The invention transforms the screening approach by changing from direct viral enzyme assays to a yeast-based phenotypic screening system. This parameter change enables high-throughput automation while preserving the ability to detect inhibitors of RNA capping enzymes through their effect on yeast cell viability and growth.
2Reliability
If viral RNA capping enzymes are targeted to develop attenuated virus strains, then live attenuated vaccines can be created, but the complexity of identifying effective attenuation mutations increases
Solution Approach 1:
The yeast-based platform enables the system to self-identify attenuation mutations through phenotypic screening. By expressing viral RNA capping enzymes in yeast and screening for mutations that reduce enzyme function, the system automatically identifies candidate attenuation mutations without requiring complex external analysis for each mutant strain.
Solution Approach 2:
The yeast expression platform serves multiple functions: it expresses viral RNA capping enzymes, enables high-throughput mutagenesis screening, and provides phenotypic readouts for identifying attenuation mutations. This multi-functional approach simplifies the overall process of developing attenuated virus strains for vaccine development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the rapid development of broad-spectrum antivirals and live attenuated vaccines by selectively targeting viral RNA capping enzymes, improving virus biocontainment and immune response stimulation.
Implementation Method 1
Methyltransferase that catalyzes the methylation at the N7 position of guanine at cap-0 and 2'-O methylation at cap-1 position using S-adenosylmethionine (AdoMet) as a cofactor
Implementation Method 2
yeast-based phenotypic platforms for characterization and targeting of viral genome encoded essential RNA capping enzymes
Data Source
AI summary
The emergence of zoonotic pathogenic viruses has accentuated the need to develop broad-spectrum antivirals and vaccines. Highly modular yeast-based phenotypic platforms for characterization and targeting of RNA capping enzymes from emerging pathogens including coronaviruses, MPV, ASFV, and WNV, are disclosed herein. This platform can identify key amino acid residues and protein domains. Inactivation and attenuation mutations in viral enzymes are also disclosed herein. This platform is applied to vertebrate RNA capping enzymes, demonstrating use for high-throughput phenotypic screening. The disclosed platforms are highly modular and can be adapted for RNA capping enzymes from viruses and variants that emerge in the future.